|
Phase III COVID-19 Vaccines
This site presents an alphabetically-ordered list of COVID-19 vaccines that are currently in Phase III clinical trials as of July 23, 2022.
Contents:
- AG0302-COVID19
- ARCoV
- ARCT-154
- AZD2816
- BBV154
- COVI-VAC
- COVID-19 subunit vaccine by HIPRA
- COVID-19 subunit vaccine by PT Bio Farma
- DelNS1-2019-nCoV-RBD-OPT1
- DS-5670a
- GEMCOVAC-19
- GRAd-CoV2
- GX-19
- IIBR-100
- INO-4800
- KD-414
- LVRNA009
- LYB001
- mRNA-1273.211
- mRNA-1273.214
- mRNA-1273.529
- Nanocovax
- NDV-HXP-S
- Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited
- PIKA Recombinant COVID-19 Vaccine
- Recombinant SARS-CoV-2 vaccine (Sf9 cell)
- ReCOV
- S-268019
- SCB-2019
- SCTV01C
- UB-612
- V-01
- VAT00002
- AG0302-COVID19
- Clinical trial ID:
- Phase II/III: NCT04655625
- Age subgroups: 18 years and above
- Location: Japan
- Type: DNA vaccine
- Manufacturer: AnGes, Inc.
- VIOLIN: 5882
- VO: VO_0005322
- ARCoV
- Clinical trial ID:
- Phase III: NCT04847102
- Age subgroups: 18 years and above
- Location: China
- Phase II: ChiCTR2100041855
- Age subgroups: 18-59 years
- Location: China
- Phase I: ChiCTR2000034112
- Age subgroups: 18-59 years, 60 years and above
- Location: China
- Phase I: ChiCTR2000039212
- Age subgroups: 18-59 years
- Location: China
- Type: mRNA vaccine
- Manufacturer: Academy of Military Sciences, Walvax Biotech.
- Publications:
- Zhang et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020; 182(5); 1271-1283. [PubMed: 32795413].
- VIOLIN: 5783
- VO: VO_0005161
- ARCT-154
- Clinical trial ID:
- Phase III: ISRCTN15779782
- Age subgroups: 16 years and above
- Location: Switzerland
- Phase II/III: NCT05012943
- Age subgroups: 18 years and above
- Location: Unknown
- Type: RNA vaccine
- Manufacturer: Arcturus Therapeutics, Inc.
- VIOLIN: 5884
- VO: VO_0005331
- AZD2816
- Clinical trial ID:
- Phase II/III: NCT04973449
- Age subgroups: 18 years and above
- Location: Brazil, UK
- Type: Recombinant vector vaccine
- Manufacturer: AstraZeneca, University of Oxford
- VIOLIN: 5881
- VO: VO_0005319
- BBV154
- Clinical trial ID:
- Phase I: NCT04751682
- Age subgroups: 18-60 years
- Location: India
- Type: Recombinant vector vaccine
- Manufacturer: Bharat Biotech International Limited
- VIOLIN: 5839
- VO: VO_0005174
- COVI-VAC
- Clinical trial ID:
- Phase III: ISRCTN15779782
- Age subgroups: 16 years and above
- Location: Switzerland
- Phase I: NCT04619628
- Age subgroups: 18-30 years
- Location: UK
- Type: Live, attenuated vaccine
- Manufacturer: Codagenix, Inc.
- VIOLIN: 5824
- VO: VO_0005187
- COVID-19 subunit vaccine by HIPRA
- Clinical trial ID:
- Phase III: NCT05246137
- Age subgroups: 16 years and above
- Location: Italy, Portugal, Spain
- Phase III: NCT05303402
- Age subgroups: 18 years and above
- Location: Spain, Turkey
- Phase II: EUCTR2021-005226-26-ES
- Age subgroups: 18-64 years, 65 years and above
- Location: Spain
- Phase I/II: NCT05007509
- Age subgroups: 18-39 years
- Location: Spain
- Type: Subunit vaccine
- Manufacturer: Laboratorios Hipra, S.A.
- VIOLIN: 5883
- VO: VO_0005321
- COVID-19 subunit vaccine by PT Bio Farma
- Clinical trial ID:
- Phase III: NCT05433285
- Age subgroups: 18 years and above
- Location: Indonesia
- Phase II/III: NCT05313035
- Age subgroups: 18 years and above
- Location: Indonesia
- Phase I/II: NCT05067894
- Age subgroups: 18-59 years, 60 years and above
- Location: Indonesia
- Type: Subunit vaccine
- Manufacturer: PT Bio Farma
- VIOLIN: 5895
- VO: VO_0005343
- DelNS1-2019-nCoV-RBD-OPT1
- Clinical trial ID:
- Type: Recombinant vector vaccine
- Manufacturer: University of Hong Kong, Xiamen University, Beijing Wantai Biological Pharmacy
- VIOLIN: 5806
- VO: VO_0005087
- DS-5670a
- Clinical trial ID:
- Phase I/II/III: jRCT2071210106
- Age subgroups: 18-64 years, 65 years and above
- Location: Japan
- Phase I/II: NCT04821674
- Age subgroups: 20-64 years, 65-74 years
- Location: Japan
- Type: mRNA vaccine
- Manufacturer: Daiichi Sankyo Co., Ltd.
- VIOLIN: 5854
- VO: VO_0005245
- GEMCOVAC-19
- Clinical trial ID:
- Type: mRNA vaccine
- Manufacturer: Gennova Biopharmaceuticals Limited
- VIOLIN: 5933
- VO: VO_0005413
- GRAd-CoV2
- Clinical trial ID:
- Phase II/III: NCT04791423
- Age subgroups: 18-64 years, 65 years and older
- Location: Italy
- Phase I: NCT04528641
- Age subgroups: 18-55 years, 65-85 years
- Location: Italy
- Type: Recombinant vector vaccine
- Manufacturer: ReiThera, Leukocare, Univercells
- VIOLIN: 5787
- VO: VO_0005169
- GX-19
- Clinical trial ID:
- Phase II/III: NCT05067946
- Age subgroups: 18 years and above
- Location: South Korea
- Phase I/II: NCT04715997
- Age subgroups: 18-55 years
- Location: South Korea
- Phase I/II: NCT04445389
- Age subgroups: 18-50 years
- Location: South Korea
- Type: DNA vaccine
- Manufacturer: Genexine
- VIOLIN: 5788
- VO: VO_0005170
- IIBR-100
- Other names: BriLife
- Clinical trial ID:
- Phase II/III: NCT04990466
- Age subgroups: 18-85 years
- Location: Unknown
- Phase I/II: NCT04608305
- Age subgroups:
- Phase I: 18-55 years
- Phase II: 18-55 years, 56-85 years
- Location: Israel
- Type: Recombinant vector vaccine
- Manufacturer: Israel Institute for Biological Research, Weizmann Institute of Science
- VIOLIN: 5799
- VO: VO_0005090
- INO-4800
- Clinical trial ID:
- Phase II/III: NCT04642638
- Age subgroups:
- Phase II: 18-50 years, 51-64 years, 65 years and above
- Phase III: 18 years and above
- Location: USA
- Phase III: ISRCTN15779782
- Age subgroups: 16 years and above
- Location: Switzerland
- Type: DNA vaccine
- Manufacturer: Inovio Pharmaceuticals
- Publications:
- Tebas et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2020; 100689; . [PubMed: 33392485].
- Smith et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11(1); 2601. [PubMed: 32433465].
- VIOLIN: 5793
- VO: VO_0005172
- KD-414
- Clinical trial ID:
- Phase II/III: jRCT2071210081
- Age subgroups: 18 years and above
- Location: Japan
- Phase I/II: jRCT2071200106
- Age subgroups: 20-64 years, 65 years and above
- Location: Japan
- Type: Inactivated or "killed" vaccine
- Manufacturer: KM Biologics Co., Ltd.
- VIOLIN: 5859
- VO: VO_0005250
- LVRNA009
- Clinical trial ID:
- Phase III: NCT05428592
- Age subgroups: 18 years and above
- Location: Pakistan
- Type: mRNA vaccine
- Manufacturer: AIM Vaccine Co., Ltd.
- VIOLIN: 5925
- VO: VO_0005414
- LYB001
- Clinical trial ID:
- Phase II/III: NCT05137444
- Age subgroups: 18-59 years, 60 years and above
- Location: Unknown
- Type: Virus-like particle
- Manufacturer: Yantai Patronus Biotech Co., Ltd.
- VIOLIN: 5901
- VO: VO_0005348
- mRNA-1273.211
- Clinical trial ID:
- Phase II/III: NCT04927065
- Age subgroups: 18 years and above
- Location: USA
- Type: mRNA vaccine
- Manufacturer: Moderna
- VIOLIN: 5876
- VO: VO_0005277
- mRNA-1273.214
- Clinical trial ID:
- Phase III: NCT05436834
- Age subgroups: 6 months-5 years
- Location: USA
- Type: mRNA vaccine
- Manufacturer: Moderna
- VIOLIN: 5939
- VO: VO_0005415
- mRNA-1273.529
- Clinical trial ID:
- Phase II/III: NCT05249829
- Age subgroups: 16 years and above
- Location: United Kingdom
- Type: mRNA vaccine
- Manufacturer: Moderna
- VIOLIN: 5926
- VO: VO_0005416
- Nanocovax
- Clinical trial ID:
- Phase III: NCT04922788
- Age subgroups: 18-45 years, 45-60 years, and 61 years and above
- Location: Vietnam
- Phase I/II: NCT04683484
- Age subgroups:
- Phase I: 18-50 years
- Phase II: 12-75 years
- Location: Vietnam
- Type: Subunit vaccine
- Manufacturer: Nanogen Pharmaceutical Biotechnology
- VIOLIN: 5809
- VO: VO_0005092
- NDV-HXP-S
- Clinical trial ID:
- Phase II/III: NCT05354024
- Age subgroups: 18-59 years, 60 years and above
- Location: Brazil
- Phase I/II: NCT04764422
- Age subgroups:
- Phase I: 18-59 years
- Phase II: 18-75 years
- Location: Thailand
- Type: Recombinant vector vaccine
- Manufacturer: Icahn School of Medicine at Mount Sinai, Mahidol University
- Publications:
- Sun et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62; 103132. [PubMed: 33232870].
- VIOLIN: 5841
- VO: VO_0005235
- Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited
- Clinical trial ID:
- Phase III: NCT05374954
- Age subgroups: 18-59 years, 60 years and above
- Location: China
- Type: Inactivated or "killed" vaccine
- Manufacturer: China National Biotec Group Company Limited
- VIOLIN: 5940
- VO: VO_0005417
- PIKA Recombinant COVID-19 Vaccine
- Clinical trial ID:
- Phase II/III: NCT05463419
- Age subgroups: 18 years and above
- Location: Unknown
- Phase I: ACTRN12621001009808
- Age subgroups: 18-65 years
- Location: New Zealand
- Type: Subunit vaccine
- Manufacturer: Yisheng Biopharma
- VIOLIN: 5892
- VO: VO_0005345
- Recombinant SARS-CoV-2 vaccine (Sf9 cell)
- Clinical trial ID:
- Phase III: NCT04904471
- Age subgroups: 18 years and above
- Location: China
- Phase III: NCT04887207
- Age subgroups: 18 years and above
- Location: China
- Phase II: NCT04718467
- Age subgroups: 18-59 years, 60 years and above
- Location: China
- Type: Subunit vaccine
- Manufacturer: West China Hospital, Sichuan University
- Publications:
- Meng et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021; 6(1); 271. [PubMed: 34267185].
- VIOLIN: 5812
- VO: VO_0005095
- ReCOV
- Clinical trial ID:
- Phase II/III: NCT05084989
- Age subgroups: 18-59 years, 60 years and above
- Location: Unknown
- Phase I: NCT04818801
- Age subgroups: 18-55 years, 56-80 years
- Location: New Zealand
- Type: Subunit vaccine
- Manufacturer: Jiangsu Rec-Biotechnology
- VIOLIN: 5863
- VO: VO_0005252
- S-268019
- Clinical trial ID:
- Phase III: jRCT2031210613
- Age subgroups: 20 years and above
- Location: Japan
- Phase III: NCT05212948
- Age subgroups: 18 years and above
- Location: Vietnam
- Phase I/II: jRCT2051200092
- Age subgroups: 20-64 years
- Location: Japan
- Type: Subunit vaccine
- Manufacturer: Shionogi
- VIOLIN: 5813
- VO: VO_0005096
- SCB-2019
- Clinical trial ID:
- Phase III: NCT05012787
- Age subgroups: 18 years and above
- Location: South Africa, Ukraine
- Phase II/III: NCT04672395
- Age subgroups: 18 years and above
- Location: Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland, South Africa
- Type: Subunit vaccine
- Manufacturer: Clover Biopharmaceuticals, GSK, Dynavax
- Publications:
- Richmond et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021; S0140-6736(21)00241-5; . [PubMed: 33524311].
- VIOLIN: 5797
- VO: VO_0004994
- SCTV01C
- Clinical trial ID:
- Phase II/III: NCT05043285
- Age subgroups: 18 years and above
- Location: China
- Phase II/III: NCT05043311
- Age subgroups: 18 years and above
- Location: China
- Type: Subunit vaccine
- Manufacturer: Sinocelltech Ltd.
- VIOLIN: 5890
- VO: VO_0005337
- UB-612
- Clinical trial ID:
- Phase II/III: NCT04683224
- Age subgroups: 18-59 years, 60 years and above
- Type: Subunit vaccine
- Manufacturer: Vaxxinity
- VIOLIN: 5798
- VO: VO_0004995
- V-01
- Clinical trial ID:
- Phase III: NCT05096845
- Age subgroups: 18-59 years, 60 years and above
- Location: Philippines
- Phase III: NCT05096832
- Age subgroups: 18-59 years, 60 years and above
- Location: Pakistan
- Phase II: ChiCTR2100045107
- Age subgroups: 18-59 years, 60-69 years, 70 years and above
- Location: China
- Type: Subunit vaccine
- Manufacturer: Livzon Mabpharm Inc.
- VIOLIN: 5856
- VO: VO_0005247
- VAT00002
- Other names: VAT00008, CoV2 preS dTM
- Clinical trial ID:
- Phase III: NCT05405283
- Age subgroups: 60 years and above
- Location: France
- Phase III: NCT04904549
- Age subgroups: 18 years and above
- Location: USA, Colombia, Honduras, Japan
- Phase III: PACTR202011523101903
- Age subgroups: 18-44 years, 45-64 years, 65 years and above
- Location: Kenya
- Phase II: NCT04762680
- Age subgroups: 18 years and above
- Location: USA
- Phase I/II: NCT04537208
- Age subgroups: 18-49 years, 50 years and above
- Location: USA
- Type: Subunit vaccine
- Manufacturer: Sanofi Pasteur, GSK
- Publications:
- Goepfert et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet. 2021; 21(9); 1257-1270. [PubMed: 33887209].
- VIOLIN: 5833
- VO: VO_0005085
Provenance: All data in Cov19VaxKB originates from manual curation of various resources, including the WHO's COVID-19 Vaccine Tracker.
Note: The page was updated on July 23, 2022. Please provide us with any new information that you believe would be useful if included on the website.
|